What a disaster the HCV division is

[Anonymous]

...and PHARMA sales is influenced by reps.

 

[Anonymous]

This thread is ridiculous! Sure, there are issues like stupid metrics, field coaching reports, new managers trying to prove themselves. The marketing is a bit of a disaster, as they continue to screw everything up that they touch, like Moderiba, and Oraquick. They never tell you what's going on with speakers and the MSL's are terrible. But in all honesty, it's not that much different than most companies. Most of the people are good folks and get along. There isn't a lot of backstabbing, the leadership is a nice group of people and I like my manager and regional. There are a lot worse places to work, and this HCV division is a huge step up from my former division in rhuem.

Why do you say the "MSLs are terrible?

 

[Anonymous]

Where is Lootzie on all of this? He is the VP and its his job to make it RIGHT!!! I often feel we are not being told the truth on timing for approval, sales potential, competitive edge, bonus $s, KOL support, etc., etc,! My DM is a goofy one who seems more interested in following sports than business. Scary times!!! We need LEADERSHIP!!

 

[Anonymous]

...and PHARMA sales is influenced by reps.

If reps don't influence sales then why do companies spend millions upon millions on reps?

 

[Anonymous]

If reps don't influence sales then why do companies spend millions upon millions on reps?

Just to kiss docs' asses basically. In the current medical environment, reps have less impact then ever. The ass kissing may get you a few scripts but formulary/wholesale cost is what makes the decision for the docs when there are multiple products available for the same indication from several different pharma companies.
That's the whole point behind the mystery of the vanishing rep jobs over the last several years. Sure, for a new launch you need bodies trying to get 3 seconds of a docs time to introduce the new drug. That is only novel to them for a very limited time. Then the rep moves into the next role as "pain in the ass" and "pizza tosser". The Sunshine Act has greatly curtailed even this dipshit role.
The net cost to the patient and the insurers' cost will ultimately determine who wins the biz. Between Ocare and Medicare and commercial plans all squeezing costs, that is the true determining factor.
Gilly has left a lot of opportunity for others to compete, cost wise. But that is easier said then done. They too can cut their prices a lot to stay in the game.
Where is the rep in this whole scenario? Not needed for long.

 

[Anonymous]

Where is Lootzie on all of this? He is the VP and its his job to make it RIGHT!!! I often feel we are not being told the truth on timing for approval, sales potential, competitive edge, bonus $s, KOL support, etc., etc,! My DM is a goofy one who seems more interested in following sports than business. Scary times!!! We need LEADERSHIP!!

No, Lutz does not have to make anything right. He needs sales. That's it, that all. Sales.

 

[Anonymous]

Just to kiss docs' asses basically. In the current medical environment, reps have less impact then ever. The ass kissing may get you a few scripts but formulary/wholesale cost is what makes the decision for the docs when there are multiple products available for the same indication from several different pharma companies.
That's the whole point behind the mystery of the vanishing rep jobs over the last several years. Sure, for a new launch you need bodies trying to get 3 seconds of a docs time to introduce the new drug. That is only novel to them for a very limited time. Then the rep moves into the next role as "pain in the ass" and "pizza tosser". The Sunshine Act has greatly curtailed even this dipshit role.
The net cost to the patient and the insurers' cost will ultimately determine who wins the biz. Between Ocare and Medicare and commercial plans all squeezing costs, that is the true determining factor.
Gilly has left a lot of opportunity for others to compete, cost wise. But that is easier said then done. They too can cut their prices a lot to stay in the game.
Where is the rep in this whole scenario? Not needed for long.

With Gileads product advantages, they will not need to meet low ball prices. Their one pill solution with no errant side effect or interaction concerns, will run the whole show.

 

[Anonymous]

I heard that 43 of the 48 vertex hires have left for much better jobs. We are toast.

You are a pussee. Vertex reps too. I guess that's why you both suck.
Laughable

 

[Anonymous]

With Gileads product advantages, they will not need to meet low ball prices. Their one pill solution with no errant side effect or interaction concerns, will run the whole show.

So true. A small price concession on Gilly's part is all that will be needed to consume this market. Abbvie is late to the dance and out of step competitively speaking.

 

[Anonymous]

You are a pussee. Vertex reps too. I guess that's why you both suck.
Laughable

Clean up your language! Typical Abbvie rep!

 

[Anonymous]

Just to kiss docs' asses basically. In the current medical environment, reps have less impact then ever. The ass kissing may get you a few scripts but formulary/wholesale cost is what makes the decision for the docs when there are multiple products available for the same indication from several different pharma companies.
That's the whole point behind the mystery of the vanishing rep jobs over the last several years. Sure, for a new launch you need bodies trying to get 3 seconds of a docs time to introduce the new drug. That is only novel to them for a very limited time. Then the rep moves into the next role as "pain in the ass" and "pizza tosser". The Sunshine Act has greatly curtailed even this dipshit role.
The net cost to the patient and the insurers' cost will ultimately determine who wins the biz. Between Ocare and Medicare and commercial plans all squeezing costs, that is the true determining factor.
Gilly has left a lot of opportunity for others to compete, cost wise. But that is easier said then done. They too can cut their prices a lot to stay in the game.
Where is the rep in this whole scenario? Not needed for long.

There must be a reason that company's spend so much on reps.

 

[Anonymous]

There must be a reason that company's spend so much on reps.

Yes to protect executive jobs

 

[Anonymous]

If reps don't influence sales then why do companies spend millions upon millions on reps?

Not for long ! Dying breed of incompetent tools

 

[Anonymous]

Kadmon Layoffs

Now that Kadmon has alienated their employes and customers. It might be a good time to revisit ModaRiba. It will be much easier to get a foot in the door with Moda than with our DAA regiment

 

[Anonymous]

Remind me - - - what does a Sr. Account Executive do? How come we have rejects from other companies in these positions? This is so BOGUS!

 

[Anonymous]

Remind me - - - what does a Sr. Account Executive do? How come we have rejects from other companies in these positions? This is so BOGUS!

They don't do anything so they will be the first ones laid off. They should leavelike if possible before having anything to do with this launch.

 

[Anonymous]

They don't do anything so they will be the first ones laid off. They should leavelike if possible before having anything to do with this launch.

So true - - - Lootzie needs to reevaluate everything & should start with the no value AEs!

 

[Anonymous]

Re: Kadmon Layoffs

Now that Kadmon has alienated their employes and customers. It might be a good time to revisit ModaRiba. It will be much easier to get a foot in the door with Moda than with our DAA regiment

Says the trouser trout that can't even spell regimen.

 

[Anonymous]

Because they have great relationships with the HCV providers.
Additionally, if you can sell Infergen (consensus interferon) you can sell anything!

I don't know why we'd want to hire interferon sales reps. In case you didn't know our 3D regimen won't need interferon!

 

[Anonymous]

Clean up your language! Typical Abbvie rep!

This is what sells. Why change?